The Czech Clinical Research Institute (CCRI) will support patients and physicians in the Czech Republic and Slovakia in accessing innovative treatments by expanding Clinerion’s hospital and patient coverage into those countries. CCRI will also accelerate the development of innovative medications by offering the services and real-world data solutions of Clinerion’s Patient Network Explorer platform.
Czech Clinical Research Institute (CCRI) is a full-service contract research organization providing tailor-made solutions for clinical trials monitoring, project management and Good Clinical Practice auditing services, operating mainly in the Czech Republic and Slovakia. CCRI also offers a wide-ranging portfolio of life sciences consulting services within the areas of pharmacovigilance, quality control, regulatory affairs consulting, data management and medical writing.
CCRI will support the expansion of Clinerion’s hospital network in the Czech Republic and Slovakia, thereby expanding the coverage of patients in Patient Network Explorer in those countries. CCRI will also offer Patient Network Explorer services and solutions for real-world evidence and accelerating clinical trials to clinical research sponsors and academic researchers.
“CCRI is a great match for Clinerion in the Czech Republic and Slovakia, traditionally countries with high medical expertise and infrastructure but low trial participation,” says Ian Rentsch, CEO of Clinerion. “Expanding the coverage of Patient Network Explorer will bring patients in the two countries to greater attention when sponsors are making siting decisions.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.